Niacin More Effective Than Zetia In Dealing With Atherosclerosis
Niacin had better results in slowing down the progression of atherosclerosis than ezetimibe, or Zetia, in the ARBITER 6-HALTS trial, according to Peggy Peck, Executive Editor of MedPage Today.
Niacin as we are most familiar with it, is Vitamin B3. The niacin used for the trial was extended-release niacin or Niaspan.
Dr. Allen J. Taylor of the Walter Reed Army Medical Center, principal investigator of the trial, observed that niacin did a better job on the artery wall, and was the clear preference for add-on therapy.
"Although ezetimibe significantly reduced LDL by 19.2%, to an average of 66 mg/dL, the 'greater reductions in LDL cholesterol level in association with ezetimibe were significantly associated with an increase in carotid intima-media thickness,' according to a post hoc analysis conducted by Taylor and colleagues."
Niacin was also less likely to precipitate cardiac problems than ezetimibe.
Dr. W. Douglas Weaver, past president of the American College of Cardiology deemed niacin to be "an effective, but underutilized drug."
http://www.kevinmd.com/blog/2009/11/niacin-beats-zetia-arbiter-6halts-tr...
We value and respect the experiences of all of our HERWriters, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice although we hope you can gain knowledge from their insight.
Add a CommentComments
There are no comments yet. Be the first one and get the conversation started!